The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Open accessAbstract
In human cells, three closely related RAS genes, termed HRAS, KRAS and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and survival among others. Gain-of-function missense mutations, mostly located at codons 12, 13 and 61, constitutively activate RAS proteins and can be detected in various types of human cancers. KRAS is the most frequently mutated, followed by NRAS and HRAS. However, each isoform exhibits distinctive mutation frequency at each codon, supporting the hypothesis that different RAS mutants may lead to distinct biologic manifestations. This review is focused on the differences in signaling and phenotype, as well as on transcriptomics, proteomics and metabolomics profiles-related to individual RAS-mutated variants. Besides, association of these mutants with particular targeted outcomes and rare mutations at additional RAS codons are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 10×
“The mutations rates at each codon differ between the RAS proteins (2).”
BackgroundInfluentialRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Subtypes of Breast Cancer Show Preferential Site of Relapse
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5644 · Cited by 813
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Oberhammer, F. A., Pavelka, M., Sharma, S., Tiefenbacher, R., Purchio, A. F., Bursch, W., & Schulte-Hermann, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5408 · Cited by 668
Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 2×
“reported that NRAS and HRAS maintain the highest Golgi pool, followed by KRAS4A and KRAS4B, which are mainly located in the plasma membrane (18).”
BackgroundBiological properties of human c-Ha-ras1 genes mutated at codon 12
Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V., & Levinson, A. D. (1984) · Nature · doi:10.1038/312071a0 · Cited by 585
Gene expression profiling of breast cell lines identifies potential new basal markers
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 569
K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
Biological and biochemical properties of human rasH genes mutated at codon 61
Der, C. J., Finkel, T., & Cooper, G. M. (1986) · Cell · doi:10.1016/0092-8674(86)90495-2 · Cited by 543
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467
Roy, S., Luetterforst, R., Harding, A., Apolloni, A., Etheridge, M., Stang, E., Rolls, B., Hancock, J. F., & Parton, R. G. (1999) · Nature Cell Biology · doi:10.1038/10067 · Cited by 454
Dclk1 distinguishes between tumor and normal stem cells in the intestine
Nakanishi, Y., Seno, H., Fukuoka, A., Ueo, T., Yamaga, Y., Maruno, T., Nakanishi, N., Kanda, K., Komekado, H., Kawada, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2481 · Cited by 406
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
K-Ras is essential for the development of the mouse embryo
Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., & Katsuki, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201284 · Cited by 355
Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353
Molina, J. R., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31506-9 · Cited by 324
Esteban, L. M., Vicario-Abejón, C., Fernández-Salguero, P., Fernández-Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J. M., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1444-1452.2001 · Cited by 298
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · cited 7×
“Moreover, this inhibition was also associated with a downregulation of cyclin D1, an increase in p27 expression and hypophosphorylation of Rb (62).”
BackgroundResultInfluentialVoice, J. K., Klemke, R. L., Le, A., & Jackson, J. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17164 · Cited by 288
Analysis of the transforming potential of the human H-ras gene by random mutagenesis.
Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth, M., & Wigler, M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.13.4008 · Cited by 280
The Role of the PI3K-AKT Pathway in Melanoma
Davies, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d448c · Cited by 240
The murine N-ras gene is not essential for growth and development.
Umanoff, H., Edelmann, W., Pellicer, A., & Kucherlapati, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1709 · Cited by 234
Cholesterol and Cancer, in the Balance
Silvente-Poirot, S., & Poirot, M. (2014) · Science · doi:10.1126/science.1252787 · Cited by 222
Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
Burd, C. E., Liu, W., Huynh, M. V., Waqas, M. A., Gillahan, J. E., Clark, K. S., Fu, K., Martin, B. L., Jeck, W. R., Souroullas, G. P., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0729 · Cited by 216
Feig, L. A., & Cooper, G. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.6.2472 · Cited by 213
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Bournet, B., Muscari, F., Buscail, C., Assenat, E., Barthet, M., Hammel, P., Selves, J., Guimbaud, R., Cordelier, P., & Buscail, L. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.18 · Cited by 205
Tissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
RAS-mediated oncogenic signaling pathways in human malignancies
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179
Smith, G., Bounds, R., Wolf, H., Steele, R. J. C., Carey, F. A., & Wolf, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605534 · Cited by 174
Suppression of Ras-Induced Apoptosis by the Rac GTPase
Joneson, T., & Bar-Sagi, D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5892 · Cited by 174
Differential Activation of the Rac Pathway by Ha-Ras and K-Ras
Walsh, A. B., & Bar-Sagi, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010573200 · Cited by 173
Detection of K-ras mutations in lung carcinomas: Relationship to prognosis
(1996) · Lung Cancer · doi:10.1016/s0169-5002(96)80041-9 · Cited by 168
Association Between Specific Mutations inKRASCodon 12 and Colorectal Liver Metastasis
Margonis, G. A., Kim, Y., Spolverato, G., Ejaz, A. M., Gupta, R., Cosgrove, D., Anders, R. A., Karagkounis, G., Choti, M. A., & Pawlik, T. M. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.0313 · Cited by 162
Control of Cell Survival and Proliferation by Mammalian Eukaryotic Initiation Factor 4B
Shahbazian, D., Parsyan, A. E., Petroulakis, E., Topisirović, I., Martineau, Y., Gibbs, B. F., Svitkin, Y. V., & Sonenberg, N. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01218-09 · Cited by 138
Tyner, J. W., Erickson, H., Deininger, M. W., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., et al. (2008) · Blood · doi:10.1182/blood-2008-04-152157 · Cited by 137
Stolze, B., Reinhart, S., Bullinger, L., Fröhling, S., & Scholl, C. (2015) · Scientific Reports · doi:10.1038/srep08535 · Cited by 136
Ras proteins: paradigms for compartmentalised and isoform-specific signalling
Omerović, J., Laude, A., & Prior, I. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7133-8 · Cited by 130
Matallanas, D., Sanz-Moreno, V., Arozarena, I., Calvo, F., Agudo-Ibáñez, L., Santos, E., Berciano, M., & Crespo, P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.100-116.2006 · Cited by 130
Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors
Rocks, O., Lorentzen, A., & Bastiaens, P. I. H. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.06.007 · Cited by 127
Potenza, N., Vecchione, C., Notte, A., Rienzo, A. D., Rosica, A., Bauer, L., Affuso, A., Felice, M. D., Russo, T., Poulet, R., et al. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400397 · Cited by 126
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
Ras p21 proteins with high or low GTPase activity can efficiently transform NIH3T3 cells
Lacal, J. C., Srivastava, S. K., Anderson, P. S., & Aaronson, S. A. (1986) · Cell · doi:10.1016/0092-8674(86)90270-9 · Cited by 112
Role of protein kinase CK2 in antitumor drug resistance
Borgo, C., & Ruzzene, M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1292-y · Cited by 109
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR
Gabitova, L., Restifo, D., Gorin, A. A., Manocha, K., Handorf, E. A., Yang, D., Cai, K. Q., Klein–Szanto, A. J., Cunningham, D., Kratz, L. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.023 · Cited by 87
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
Brunelli, L., Caiola, E., Marabese, M., Broggini, M., & Pastorelli, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1958 · Cited by 85
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
Hammond, D. E., Mageean, C. J., Rusilowicz, E. V., Wickenden, J. A., Clague, M. J., & Prior, I. A. (2015) · Journal of Proteome Research · doi:10.1021/pr501191a · Cited by 81
Whipple, C. A., Young, A. L., & Korc, M. (2011) · Oncogene · doi:10.1038/onc.2011.430 · Cited by 78
Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0767-4 · Cited by 77
Hayama, T., Hashiguchi, Y., Okamoto, K., Okada, Y., Ono, K., Shimada, R., Ozawa, T., Toyoda, T., Tsuchiya, T., Iinuma, H., et al. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03344-9 · Cited by 70
Cespedes, M. V., Sancho, F. J., Guerrero, S., Parreno, M., Casanova, I., Pavon, M. A., Marcuello, E., Trias, M., Cascante, M., Capella, G., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl063 · Cited by 67
DCLK1 immunoreactivity in colorectal neoplasia
Gagliardi, G., Bellows, C. F., Goswami, M., & Passera, R. (2012) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s30281 · Cited by 61
Characterization of a novel oncogenic K-ras mutation in colon cancer
Akagi, K., Uchibori, R., Yamaguchi, K., Kurosawa, K., Tanaka, Y., & Kozu, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.091 · Cited by 56
Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., & Barni, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0650-4 · Cited by 56
Charitou, T., Srihari, S., Lynn, M. A., Jarboui, M. A., Fasterius, E., Moldovan, M. V., Shirasawa, S., Tsunoda, T., Ueffing, M., Xie, J., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0477-7 · Cited by 56
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55
Baker, N. M., Chow, H. Y., Chernoff, J., & Der, C. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1727 · Cited by 53
Lacal, J. C., & Aaronson, S. A. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4214 · Cited by 52
An Integrated Global Analysis of Compartmentalized HRAS Signaling
Santra, T., Herrero, A., Rodríguez, J., von Kriegsheim, A., Iglesias-Martinez, L. F., Schwarzl, T., Higgins, D. G., Aye, T., Heck, A. J. R., Calvo, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.038 · Cited by 49
A Novel Activating Mutation of the K-ras Gene in Human Primary Colon Adenocarcinoma
Tsukuda, K., Tanino, M., Soga, H., Shimizu, N., & Shimizu, K. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3839 · Cited by 42
Structural effects of substitutions on the p21 proteins.
Pincus, M. R., & Brandt‐Rauf, P. W. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.11.3596 · Cited by 40
Roberts, M. L., Drosopoulos, K. G., Vasileiou, I., Stricker, M., Taoufik, E., Maercker, C., Guialis, A., Alexis, Μ. N., & Pintzas, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.21386 · Cited by 40
Posch, C., Sanlorenzo, M., Vujic, I., Osés-Prieto, J. A., Cholewa, B. D., Kim, S. T., Ma, J. A., Lai, K., Zekhtser, M., Esteve‐Puig, R., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.05.098 · Cited by 40
Doll, S., Urisman, A., Osés-Prieto, J. A., Arnott, D. P., & Burlingame, A. L. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063883 · Cited by 39
Mellema, W. W., Masen-Poos, L., Smit, E. F., Hendriks, L. E. L., Aerts, J. G. J. V., Termeer, A., Goosens, M., Smit, H. J. M., van den Heuvel, M. M., van der Wekken, A. J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.012 · Cited by 36
Brunelli, L., Caiola, E., Marabese, M., Broggini, M., & Pastorelli, R. (2016) · Scientific Reports · doi:10.1038/srep28398 · Cited by 33
KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice
Tang, F., Hsieh, T., Hsu, C., Lin, H., Long, C., Cheng, K., & Tsai, E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30591 · Cited by 33
Leiser, D., Medová, M., Mikami, K., Nisa, L., Stroka, D., Blaukat, A., Bladt, F., Aebersold, D. M., & Zimmer, Y. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.001 · Cited by 30
Self-citationRosseland, C. M., Wierød, L., Flinder, L. I., Oksvold, M. P., Skarpen, E., & Huitfeldt, H. S. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21367 · Cited by 29
de Atauri, P., Benito, A., Vizán, P., Zanuy, M., Mangues, R., Marín, S., & Cascante, M. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.11.015 · Cited by 26
Trabalzini, L., & Retta, S. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-62703-791-4 · Cited by 19
Jiang, W., Jia, P., Hutchinson, K. E., Johnson, D. B., Sosman, J. A., & Zhao, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2954 · Cited by 17
Renaud, S., Guerrera, F., Seitlinger, J., Reeb, J., Voegeli, A., Legrain, M., Mennecier, B., Santelmo, N., Falcoz, P., Quoix, É., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.005 · Cited by 16
Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study
Takayama, T., Furuse, H., Kai, F., Sugiyama, T., & Ozono, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0563-2 · Cited by 4
Cited by
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells
Petri, K., Zhang, W., Ma, J., Schmidts, A., Lee, H., Horng, J. E., Kim, D. Y., Kurt, I. C., Clement, K., Hsu, J. Y., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-00901-y · Cited by 208
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
Metadata
- Authors
- Muñoz-Maldonado, C., Zimmer, Y., & Medová, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-10-18
- Volume
- 9
- Pages
- 1088-1088
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2980948969
- Cited by
- 254
- References
- 80
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.